

SECURITIES AND EXCHANGE COMMISSION

FORM 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: **2008-08-29** | Period of Report: **2008-08-28**  
SEC Accession No. **0001275011-08-000047**

([HTML Version](#) on [secdatabase.com](#))

FILER

**VIREXX MEDICAL CORP**

CIK: **1275011** | IRS No.: **000000000** | Fiscal Year End: **1231**  
Type: **6-K** | Act: **34** | File No.: **001-32608** | Film No.: **081046643**  
SIC: **2836** Biological products, (no disgnostic substances)

Mailing Address  
8223 ROPER ROAD  
EDMONTON A0 T6E 6S4

Business Address  
8223 ROPER ROAD  
EDMONTON A0 T6E 6S4  
(780) 433-4411



**FORM 6-K**

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

For the month ended

August 2008

Commission File Number

1-32608

**VIREXX MEDICAL CORP.**

(Translation of registrant's name into English)

8223 Roper Road NW, Edmonton, Alberta, Canada T6E 6S4

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- \_\_\_\_\_

**EXHIBIT LIST**

<u>Exhibit</u>	<u>Description</u>
99.1	Press Release Announcing Receipt of Delisting Notification from AMEX Regarding Non-Compliance with Listing Standards

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

***VIREXX MEDICAL CORP.***

Date: August 28, 2008

By: */s/ Brent Johnston*

Brent Johnston  
Chief Financial Officer

---









**REX**

**TSX: VIR**

*ViRexx*

*Corp.*

**Immediate Release**

---

*Medical*



## VIREXX RECEIVES DELISTING NOTIFICATION FROM AMEX REGARDING NON-COMPLIANCE WITH LISTING STANDARDS

**EDMONTON, ALBERTA – August 28, 2008** – ViRexx Medical Corp. (TSX:VIR, AMEX:REX), a company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for living. Its platform technologies include product candidates for the treatment of Hepatitis B, Hepatitis C, avian influenza viral infections, biodefence and nanoparticle applications, select solid tumors and late-stage ovarian cancer, received notification from the American Stock Exchange (“AMEX” or “Exchange”) that the Company’s plan to regain compliance with ongoing listing standards of the AMEX was not accepted and intends to initiate the delisting process unless the Company submits an appeal by August 29, 2008.

Since submitting the plan, the Company has also fallen out of compliance with an additional listing standard. Specifically, the Company is not in compliance with Section 1003(f)(iv) of the Company Guide which states that the Exchange will normally consider suspending dealings in or removing from the list, a company that fails or refuses to pay, when due, any applicable listing fees established by the Exchange. The Company satisfied its outstanding balance payable to the Exchange for listing fees on August 28, 2008.

On May 6, 2008, the Company received notification from the AMEX that it was no longer in compliance with certain of the AMEX’s continued listing standards set forth in Part 10 of the AMEX Company Guide (“Company Guide”) and the Company has therefore become subject to the procedures and requirements of Section 1009 of the Company Guide.

Specifically, the Company is not in compliance with Section 1003(a)(i) of the Company Guide with stockholders’ equity of less than \$2,000,000 and losses from continuing operations and/or net losses in two out of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide with stockholders’ equity of less than \$4,000,000 and losses from continuing operations and/or net losses in three out of its four most recent fiscal years, Section 1003(a)(iii) of the Company Guide with stockholders’ equity of less than \$6,000,000 and losses from continuing operations and/or net losses in its five most recent fiscal years, and Section 1003(a)(iv) of the Company Guide in that it has sustained losses which are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the AMEX, as to whether such company will be able to continue operations and/or meet its obligations as they mature.

In order to maintain its AMEX listing, the Company submitted a plan to the AMEX addressing how it intends to regain compliance with Section 1003(a)(iv) of the Company Guide by November 6, 2008 and Sections 1003(a)(i), (ii), (iii) of the Company Guide by November 6, 2009 .

The Company has submitted an application for appeal prior to the August 29, 2008 deadline.

### **About ViRexx Medical Corp.**

ViRexx is a Canadian-based development-stage biotech company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for living. Our platform technologies include product candidates for the treatment of Hepatitis B, Hepatitis C, avian influenza viral infections, biodefence and nanoparticle applications, select solid tumors and late-stage ovarian cancer. For additional information about ViRexx, please see [www.virexx.com](http://www.virexx.com).

THE TSX HAS NOT APPROVED OR DISAPPROVED OF THE INFORMATION CONTAINED HEREIN

*This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.*

### **For more information, please contact:**

---

Darrell Elliott  
Chairman and Chief Executive Officer  
ViRexx Medical Corp.  
Tel: (780) 433-4411  
Fax: (780) 436-0068  
[investor@virexx.com](mailto:investor@virexx.com)

---

Brent Johnston  
Chief Financial Officer  
ViRexx Medical Corp.  
Tel: (780) 433-4411  
Fax: (780) 436-0068  
[investor@virexx.com](mailto:investor@virexx.com)

---



